Edition:
United States

La Jolla Pharmaceutical Co (LJPC.OQ)

LJPC.OQ on NASDAQ Stock Exchange Capital Market

30.80USD
20 Apr 2018
Change (% chg)

$0.51 (+1.68%)
Prev Close
$30.29
Open
$30.28
Day's High
$31.04
Day's Low
$30.16
Volume
113,336
Avg. Vol
201,155
52-wk High
$41.24
52-wk Low
$22.68

Chart for

About

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $787.48
Shares Outstanding(Mil.): 25.57
Dividend: --
Yield (%): --

Financials

  LJPC.OQ Industry Sector
P/E (TTM): -- 185.16 33.25
EPS (TTM): -5.40 -- --
ROI: -141.71 -0.71 13.13
ROE: -168.89 -2.76 14.96

BRIEF-La Jolla PharmaAnnounces Launch Of Giapreza In United States

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES LAUNCH OF GIAPREZA™ (ANGIOTENSIN II) IN THE UNITED STATES

Mar 22 2018

BRIEF-La Jolla Pharmaceutical Announces Pricing Of Public Offering Of Common Stock

* SAYS PUBLIC OFFERING OF 3.40 MILLION COMMON SHARES PRICED AT $29.50PER SHARE

Mar 15 2018

BRIEF-La Jolla Pharmaceutical Company Announces $100 Million Public Offering Of Common Stock

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES $100 MILLION PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 14 2018

BRIEF-La Jolla Pharmaceutical Q4 Loss Per Share $1.74

* MPANY ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS

Feb 22 2018

BRIEF-La Jolla Pharmaceutical Announces Treatment Of First Patient In Giapreza Pediatric Study

* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES THE TREATMENT OF FIRST PATIENT IN GIAPREZA (ANGIOTENSIN II) PEDIATRIC STUDY Source text for Eikon: Further company coverage:

Feb 21 2018

BRIEF-La Jolla Pharmaceutical Says Established Wholesale Acquisition Cost of Single-Dose Vial Of Giapreza At $1,500/ Vial

* LA JOLLA PHARMACEUTICAL CO - ESTABLISHED WHOLESALE ACQUISITION COST OF $1,500 PER VIAL FOR A 1 ML, SINGLE-DOSE, 2.5 MG/ML VIAL OF GIAPREZA Source text: (http://bit.ly/2nm3hfv) Further company coverage:

Jan 30 2018

BRIEF-Broadfin Capital Reports 5 Percent Passive Stake In La Jolla Pharmaceutical - SEC Filing‍​

* BROADFIN CAPITAL LLC REPORTS 5 PERCENT PASSIVE STAKE IN LA JOLLA PHARMACEUTICAL CO AS OF JAN 9 - SEC FILING‍​ Source text: (http://bit.ly/2D4NbRm) Further company coverage:

Jan 11 2018

BRIEF-La Jolla Pharmaceutical Says Cash Resources Are Expected To Fund Co Into Second Half Of 2018

* LA JOLLA PHARMACEUTICAL SAYS CASH RESOURCES ARE EXPECTED TO FUND CO INTO SECOND HALF OF 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2BTfmOK) Further company coverage:

Dec 29 2017

FDA approves La Jolla's low blood pressure drug

La Jolla Pharmaceutical said on Thursday the U.S. Food and Drug Administration had approved its drug, Giapreza, to treat dangerously low blood pressure.

Dec 21 2017

FDA approves La Jolla's low blood pressure drug

Dec 21 La Jolla Pharmaceutical said on Thursday the U.S. Food and Drug Administration had approved its drug, Giapreza, to treat dangerously low blood pressure.

Dec 21 2017

Competitors

  Price Chg
Galectin Therapeutics Inc (GALT.OQ) $3.46 -0.21
Merck & Co., Inc. (MRK.N) $58.83 +0.19
Roche Holding Ltd. (ROG.S) CHF215.65 -0.85
Roche Holding Ltd. (RO.S) CHF220.00 -0.20
Novartis AG (NOVN.S) CHF76.08 -1.20
Celltrion, Inc. (068270.KS) ₩269,000.00 +2,500.00
Kyowa Hakko Kirin Co Ltd (4151.T) ¥2,373 -3.00
Astellas Pharma Inc (4503.T) ¥1,582 -10.00

Earnings vs. Estimates